Importer of Controlled Substances; Notice of Application, 36683-36684 [2010-15528]
Download as PDF
<![CDATA[
Federal Register / Vol. 75, No. 123 / Monday, June 28, 2010 / Notices
DEPARTMENT OF JUSTICE
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on March 11, 2010,
Wildlife Laboratories Inc., 1401 Duff
Drive, Suite 400, Fort Collins, Colorado
80524, made application by renewal to
the Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of Carfentanil (9743), a
basic class of controlled substance listed
in schedule II.
The company plans to manufacture
the above listed controlled substance for
sale to veterinary pharmacies, zoos, and
for other animal and wildlife
applications.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substances,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such comments or objections
should be addressed, in quintuplicate,
to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than August 27, 2010.
Dated: June 17, 2010.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
jlentini on DSKJ8SOYB1PROD with NOTICES
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on March 15, 2010,
Penick Corporation, 33 Industrial Road,
Pennsville, New Jersey 08070, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the basic classes of controlled
substances listed in schedule II:
VerDate Mar<15>2010
21:02 Jun 25, 2010
Schedule
Jkt 220001
Dated: June 17, 2010.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
The company plans to manufacture
the listed controlled substances as bulk
controlled substance intermediates for
distribution to its customers.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substances,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such comments or objections
should be addressed, in quintuplicate,
to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than August 27, 2010.
Dated: June 17, 2010.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2010–15559 Filed 6–25–10; 8:45 am]
BILLING CODE 4410–09–P
Manufacturer of Controlled
Substances Notice of Application
DEPARTMENT OF JUSTICE
II
II
II
II
II
II
II
II
II
II
II
II
Drug Enforcement Administration
BILLING CODE 4410–09–P
Cocaine (9041) .............................
Codeine (9050) .............................
Dihydrocodeine (9120) .................
Oxycodone (9143) ........................
Hydromorphone (9150) ................
Diphenoxylate (9170) ...................
Ecgonine (9180) ...........................
Hydrocodone (9193) .....................
Morphine (9300) ...........................
Oripavine (9330) ...........................
Thebaine (9333) ...........................
Oxymorphone (9652) ...................
Springfield, Virginia 22152; and must be
filed no later than August 27, 2010.
DEPARTMENT OF JUSTICE
[FR Doc. 2010–15527 Filed 6–25–10; 8:45 am]
Drug
Schedule
Drug
Drug Enforcement Administration
Pursuant to § 1301.33(a), Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on March 29, 2010,
Siegfried (USA), 33 Industrial Park
Road, Pennsville, New Jersey 08070,
made application by letter to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
Gamma Hydroxybutyric Acid (2010), a
basic class of controlled substance listed
in schedule I.
The company plans to manufacture
the listed controlled substance in bulk
for sale to its customers.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substances,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such comments or objections
should be addressed, in quintuplicate,
to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
PO 00000
Frm 00055
Fmt 4703
36683
Sfmt 4703
[FR Doc. 2010–15558 Filed 6–25–10; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Application
Pursuant to 21 U.S.C. 958(i), the
Attorney General shall, prior to issuing
a registration under this section to a
bulk manufacturer of a controlled
substance in schedule I or II, and prior
to issuing a regulation under 21 U.S.C.
952(a)(2) authorizing the importation of
such a substance, provide
manufacturers holding registrations for
the bulk manufacture of the substance
an opportunity for a hearing.
Therefore, in accordance with Title 21
Code of Federal Regulations (CFR),
1301.34(a), this is notice that on April
12, 2010, Boehringer Ingelheim
Chemicals, Inc., 2820 N. Normandy
Drive, Petersburg, Virginia 23805, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as an importer of
Phenylacetone (8501), a basic class of
controlled substance listed in schedule
II.
The company plans to import the
listed controlled substance to bulk
manufacture amphetamine.
Any bulk manufacturer who is
presently, or is applying to be,
registered with DEA to manufacture
such basic class of controlled substance
may file comments or objections to the
issuance of the proposed registration,
and may, at the same time, file a written
request for a hearing on such
application pursuant to 21 CFR 1301.43
and in such form as prescribed by 21
CFR 1316.47.
Any such comments or objections
should be addressed, in quintuplicate,
to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than July 28, 2010.
This procedure is to be conducted
simultaneously with, and independent
of, the procedures described in 21 CFR
1301.34(b), (c), (d), (e), and (f). As noted
in a previous notice published in the
Federal Register on September 23, 1975,
E:\FR\FM\28JNN1.SGM
28JNN1
36684
Federal Register / Vol. 75, No. 123 / Monday, June 28, 2010 / Notices
(40 FR 43745–46), all applicants for
registration to import a basic class of
any controlled substance in schedule I
or II are, and will continue to be,
required to demonstrate to the Deputy
Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a); 21 U.S.C. 823(a); and 21
CFR 1301.34(b), (c), (d), (e) and (f) are
satisfied.
Dated: June 17, 2010.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2010–15528 Filed 6–25–10; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Application
Pursuant to 21 U.S.C. 958(i), the
Attorney General shall, prior to issuing
a registration under this Section to a
bulk manufacturer of a controlled
substance in schedule I or II, and prior
to issuing a regulation under 21 U.S.C.
952(a)(2) authorizing the importation of
such a substance, provide
manufacturers holding registrations for
the bulk manufacture of the substance
an opportunity for a hearing.
Therefore, in accordance with 21 CFR
1301.34(a), this is notice that on March
22, 2010, Cerilliant Corporation, 811
Paloma Drive, Suite A, Round Rock,
Texas 78665–2402, made application by
letter to the Drug Enforcement
Administration (DEA) to be registered as
an importer of the basic classes of
controlled substances listed in schedule
I:
Drug
Schedule
jlentini on DSKJ8SOYB1PROD with NOTICES
Racemoramide (9645) ..................
Tilidine (9750) ...............................
21:02 Jun 25, 2010
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2010–15523 Filed 6–25–10; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on April 27, 2010,
Varian, Inc., 25200 Commercentre
Drive, Lake Forest, California 92630–
8810, made application by renewal to
the Drug Enforcement Administration
(DEA) as a bulk manufacturer of the
basic classes of controlled substances
listed in schedule II:
I
I
Drug
The company plans to import small
quantities of the listed controlled
substances for the manufacture of
analytical reference standards.
Any bulk manufacturer who is
presently, or is applying to be,
registered with DEA to manufacture
such basic classes of controlled
substances may file comments or
objections to the issuance of the
proposed registration and may, at the
same time, file a written request for a
hearing on such application pursuant to
21 CFR 1301.43, and in such form as
prescribed by 21 CFR 1316.47.
VerDate Mar<15>2010
Any such comments or objections
should be addressed, in quintuplicate,
to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than July 28, 2010.
This procedure is to be conducted
simultaneously with, and independent
of, the procedures described in 21 CFR
1301.34(b), (c), (d), (e), and (f). As noted
in a previous notice published in the
Federal Register on September 23, 1975,
(40 FR 43745–46), all applicants for
registration to import a basic class of
any controlled substance listed in
schedule I or II are, and will continue
to be, required to demonstrate to the
Deputy Assistant Administrator, Office
of Diversion Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a); 21 U.S.C. 823(a); and 21
CFR 1301.34(b), (c), (d), (e), and (f) are
satisfied.
Jkt 220001
Schedule
Phencyclidine (7471) ....................
1piperidinocyclohexanecarbonitrile (8603).
Benzoylecgonine (9180) ...............
II
II
II
The company plans to manufacture
small quantities of the listed controlled
substances for use in diagnostic
products.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substances,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
PO 00000
Frm 00056
Fmt 4703
Sfmt 4703
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than August 27, 2010.
Dated: June 17, 2010.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2010–15526 Filed 6–25–10; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–326R]
Proposed Revised Assessment of
Annual Needs for the List I Chemicals
Ephedrine, Pseudoephedrine, and
Phenylpropanolamine for 2010
AGENCY: Drug Enforcement
Administration (DEA), Justice.
ACTION: Notice of proposed revised 2010
assessment of annual needs for the List
I chemicals ephedrine,
pseudoephedrine, and
phenylpropanolamine.
SUMMARY: This notice proposes revised
2010 assessment of annual needs for the
List I chemicals ephedrine,
pseudoephedrine, and
phenylpropanolamine.
DATES: Written comments must be
postmarked, and electronic comments
must be sent, on or before July 28, 2010.
ADDRESSES: To ensure proper handling
of comments, please reference ‘‘Docket
No. DEA–326R’’ on all written and
electronic correspondence. Written
comments being sent via regular mail
should be sent to the Deputy Assistant
Administrator, Office of Diversion
Control, Drug Enforcement
Administration, Washington, DC 20537,
Attention: DEA Federal Register
Representative/ODL. Written comments
sent via express mail should be sent to
DEA Headquarters, Attention: DEA
Federal Register Representative/ODL,
8701 Morrissette Drive, Springfield,
Virginia 22152. Comments may be
directly sent to DEA electronically by
sending an electronic message to
dea.diversion.policy@usdoj.gov.
However, persons wishing to request a
hearing should note that such requests
must be written and manually signed;
requests for a hearing will not be
accepted via electronic means. DEA will
accept attachments to electronic
E:\FR\FM\28JNN1.SGM
28JNN1
]]>Agencies
[Federal Register Volume 75, Number 123 (Monday, June 28, 2010)]
[Notices]
[Pages 36683-36684]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-15528]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances; Notice of Application
Pursuant to 21 U.S.C. 958(i), the Attorney General shall, prior to
issuing a registration under this section to a bulk manufacturer of a
controlled substance in schedule I or II, and prior to issuing a
regulation under 21 U.S.C. 952(a)(2) authorizing the importation of
such a substance, provide manufacturers holding registrations for the
bulk manufacture of the substance an opportunity for a hearing.
Therefore, in accordance with Title 21 Code of Federal Regulations
(CFR), 1301.34(a), this is notice that on April 12, 2010, Boehringer
Ingelheim Chemicals, Inc., 2820 N. Normandy Drive, Petersburg, Virginia
23805, made application by renewal to the Drug Enforcement
Administration (DEA) to be registered as an importer of Phenylacetone
(8501), a basic class of controlled substance listed in schedule II.
The company plans to import the listed controlled substance to bulk
manufacture amphetamine.
Any bulk manufacturer who is presently, or is applying to be,
registered with DEA to manufacture such basic class of controlled
substance may file comments or objections to the issuance of the
proposed registration, and may, at the same time, file a written
request for a hearing on such application pursuant to 21 CFR 1301.43
and in such form as prescribed by 21 CFR 1316.47.
Any such comments or objections should be addressed, in
quintuplicate, to the Drug Enforcement Administration, Office of
Diversion Control, Federal Register Representative (ODL), 8701
Morrissette Drive, Springfield, Virginia 22152; and must be filed no
later than July 28, 2010.
This procedure is to be conducted simultaneously with, and
independent of, the procedures described in 21 CFR 1301.34(b), (c),
(d), (e), and (f). As noted in a previous notice published in the
Federal Register on September 23, 1975,
[[Page 36684]]
(40 FR 43745-46), all applicants for registration to import a basic
class of any controlled substance in schedule I or II are, and will
continue to be, required to demonstrate to the Deputy Assistant
Administrator, Office of Diversion Control, Drug Enforcement
Administration, that the requirements for such registration pursuant to
21 U.S.C. 958(a); 21 U.S.C. 823(a); and 21 CFR 1301.34(b), (c), (d),
(e) and (f) are satisfied.
Dated: June 17, 2010.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 2010-15528 Filed 6-25-10; 8:45 am]
BILLING CODE 4410-09-P
